Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Merck Sharp & Dohme (UK) Limited, 120 Moorgate, London, EC2M 6UR, United Kingdom
Lagevrio 200 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsule. Swedish Orange, opaque, size 0 (approximately 21.7 mm x 7.6 mm) hard capsule, printed with MSD corporate logo on the cap and “82” on the body in white ink. |
Each hard capsule contains 200 mg of molnupiravir.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Molnupiravir |
Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. Molnupiravir is a prodrug that is metabolised to the ribonucleoside analogue N-hydroxycytidine (NHC) which distributes into cells where it is phosphorylated to form the pharmacologically active ribonucleoside triphosphate (NHC-TP). |
| List of Excipients |
|---|
|
Capsule content: Croscarmellose sodium (E468) Capsule shell: Hypromellose (E464) Printing ink: Butyl alcohol |
High-density polyethylene (HDPE) bottles with a polypropylene closure containing 40 capsules.
Merck Sharp & Dohme (UK) Limited, 120 Moorgate, London, EC2M 6UR, United Kingdom
PLGB 53095/0089
Date of first authorisation: 4th November 2021
| Drug | Countries | |
|---|---|---|
| LAGEVRIO | Japan, New Zealand, Romania, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
